Sanofi Strikes $700M Deal with Belharra To Fight Immunological Diseases

Belharra Therapeutics has unveiled a new strategic alliance with Sanofi, a leading global entity, aimed at advancing the creation of small molecule treatments for immunological disorders. As part of the deal, the San Diego-based innovative chemoproteomics firm will be granted an initial payment of $40 million.

Furthermore, according to the press release dated 18th June, the company has the potential to receive payments totaling $700 million for research, development, achieving commercial milestones, and royalties in the long run. Belharra, known for its expertise in developing non-covalent small molecules by identifying binding pockets on the proteome, will utilize its exclusive screening platform to confirm several undisclosed targets selected by Sanofi.

At that stage, Sanofi will assume control and begin the following stages of preclinical, clinical, and commercial activities for its selected candidates. John Bertin, Global Head of Immunology and Inflammation Research at Sanofi, highlighted the focus on exploring targets that were previously considered difficult to target in a statement regarding the agreement. Belharra’s unique platform, which is designed to provide validated insights into challenging protein targets by identifying binding pockets and protein interactions across different cell types, has also attracted interest from other pharmaceutical companies.